Holly Gooding, a researcher at Harvard Medical School in Boston who wasn’t involved in the study.Among the young adults in the current study, higher BMIs were associated with an increased risk of high blood pressure, researchers report in Circulation.9 is overweight, 30 or above is obese and 40 or higher is morbidly or extremely obese. Centers for Disease Control and Prevention has a free online BMI calculator here: bit."No matter what they weigh, young people can still take steps to minimize their risk of heart attacks and other cardiovascular problems, Gooding added. The results also suggest that a higher BMI causes so-called left ventricular mass index to be higher, reflecting enlargement of the left ventricle in the heart, which pumps blood around the body, she said.Most previous research on the relationship between body mass index (BMI) - a measure of weight adjusted for height - and cardiovascular events like heart attacks has focused on older adultsResearchers looked the relationship between BMI and routinely collected cardiovascular data, such as blood pressure and heart rate, in more than 3000 17-year-olds born in the 1990s. Diastolic pressure indicates the pressure when the heart rests between beats. (The U.The study wasn’t a true controlled experiment designed to prove whether or how excess weight Injection needle assembly machine for sale might directly cause heart problems.9 is considered healthy, 25 to 29. "Our results support efforts to reduce BMI to within a normal, healthy range from a young age to prevent later cardiovascular disease. "Whether this is due to the increased metabolic demands of their higher weight, or increased inflammation generated by the fat cells themselves, or something else is unclear, as these mechanisms weren’t addressed in this study," Gooding said by email."

They also examined cardiovascular scans from 400 21-year-olds who were at higher genetic risk for an unhealthy BMI. "What we do know is that it is not simply due to lower physical activity or less optimal dietary patterns in these individuals, as these lifestyle factors were not associated with the genes for BMI. Systolic pressure reflects the pressure blood exerts against artery walls when the heart beats."A BMI of 18.)In the current study, the 17-year-olds with weight data available had an average BMI of about 23, in the healthy range, and average blood pressure readings of about 119 mmHG over 64 mmHG, also within a healthy range.

Even in early adulthood, being overweight is associated with an increased risk of high blood pressure and heart muscle damage that may set the stage for cardiovascular diseases later in life, a UK study suggests.The American Heart Association defines hypertension, or high blood pressure, as a systolic reading of 130 mmHg or higher and diastolic readings of 80 mmHg or higher.ly/2ylWKJC. "These findings suggest that BMI is likely to have an adverse causal impact on cardiac structure even in young adults," Wade said by email.5 to 24. "Everyone can protect their heart by staying physically active, eating a diet rich in fruits and vegetables and whole grains and low in sodium and added sugars, and avoiding smoking," Gooding said.

It is hoped that the findings could help fine-tune treatment for cancer patients and revitalise an interest in the use of microtubule-targeting agents (MTAs) which are commonly used as chemotherapies in cancer patients..Washington: A group of scientists has worked to develop a new technique in order to fine-tune cancer treatment.""This is really important because MTAs are already in clinic and commonly used as chemotherapies such as paclitaxel in cancer patients.Dr Robinson said, "This protein, Beta3-integrin, has been the focus of drug design over the last two decades because its expression is vastly increased in endothelial cells during blood vessel recruitment to tumours.The study appears in the journal EMBO Reports. Microtubules are protein structures in cells that help them move and divide."

The research team has long looked at Beta3-integrin as a better anti-angiogenic target because the protein is not expressed in normal blood vessels, but is expressed in tumour blood vessels. Targeting angiogenesis is therefore seen as crucial in many anti-cancer strategies", continued Robinson. This reduced the potential for unwanted side effects."Anti-angiogenic drugs stop tumours from growing their own blood vessels, and this, in turn, can slow the growth of cancer, or shrink it. The study revealed that tumour growth is better-reduced in mice when the expression of a particular protein called Beta3-integrin is targeted in combination with drugs that are already used in cancer patients. We found that targeting the protein Beta3-integrin in combination with the use of microtubule-targeting agents (MTAs) could be a good way to stop tumours recruiting a blood supply to grow. Meanwhile, Beta3-integrin inhibitors have been at the centre of cancer drug design for over 20 years and are well-tolerated in clinical trials", Robinson elaborated. "

However many anti-angiogenetic therapies target proteins that help the functioning of a patients normal blood supply - and this can lead to nasty side effects including haemorrhage, strokes, high blood pressure, and fatigue.Now the team has shown that targeting Beta3-integrin in combination with microtubule-targeting agents, which are widely used in cancer patients, works better than targeting Beta3-integrin alone.Specifically, the Robinson lab looked at how Beta3-integrin and microtubules interact with one another in the cells that line blood vessels (endothelial cells), and showed that microtubules behave differently when Beta3-integrin levels are reduced; the microtubules become more sensitive to the chemotherapies that are used to hit them.Lead researcher Stephen Robinson said, "Tumours must recruit their own blood supply to grow beyond a very small size and this process is called angiogenesis".According to a study conducted by the University of East Anglia, cancer therapies that cut off blood supply to a tumour could be more effective in combination with Safety injection needle for sale existing chemotherapeutic drugs.